Valganciclovir as CMV reactivation prophylaxis in patients receiving alemtuzumab for marrow failure syndromes.
Antonio M
AM
Risitano
Bianca
B
Serio
Carmine
C
Selleri
Bruno
B
Rotoli
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use*; D001855:Bone Marrow Diseases / Q000188:drug therapy* / Q000503:physiopathology; D017322:Clinical Trials, Phase II as Topic; D015774:Ganciclovir / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D012008:Recurrence; D013577:Syndrome; D000077562:Valganciclovir
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000998:Antiviral Agents; D007166:Immunosuppressive Agents; D000074323:Alemtuzumab; D000077562:Valganciclovir; D015774:Ganciclovir